Acadia Pharmaceuticals
ACAD
ACAD
273 hedge funds and large institutions have $6.41B invested in Acadia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 97 increasing their positions, 78 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
273
Holders Change
+42
Holders Change %
+18.18%
% of All Funds
5.39%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
71
Increased
97
Reduced
78
Closed
26
Calls
$86.9M
Puts
$85M
Net Calls
+$1.86M
Net Calls Change
-$25M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$566M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
$33.1M |
| 3 |
UBS AM
Chicago,
Illinois
|
$36.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
$112M |
| 5 |
BlackRock
New York
|
$438M |
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
$65.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
$894M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
$61.1M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
$53.5M |
| 5 |
D.E. Shaw & Co
New York
|
$58.9M |
